Lu Yifan, Chen Songhai, Wang Qingqing, Zhang Jie, Pei Xuanzeng
Department of Hepatobiliary Surgery, The First Hospital of Jiaxing, Jiaxing, Zhejiang, China.
J Oncol. 2022 Aug 26;2022:1939368. doi: 10.1155/2022/1939368. eCollection 2022.
Hepatocellular carcinoma (HCC) is a highly aggressive malignant disease, and numerous studies have shown that certain functional long noncoding RNAs (lncRNAs) are implicated in the progression of several cancers. The purpose of the research was to determine, using a database, bioinformatics, and statistical analysis, whether or not lncRNA PRR7-AS1 (PRR7-AS1) was related to HCC. TCGA datasets were used to conduct research on the PRR7-AS1 expression pattern in HCC. In order to evaluate the efficacy of GIHCG as a prognostic tool, both survival and Cox regression analyses were carried out. Furthermore, an investigation of the connection between the expression of PRR7-AS1 and immune infiltration in HCC was carried out. In this study, we identified 125 lncRNAs that were significantly dysregulated in HCC and were associated with long-term survival. Among the above 125 lncRNAs, our attention focused on PRR7-AS1. We found that PRR7-AS1 expressions were distinctly overexpressed in HCC samples compared with nontumor samples. ROC assays revealed that PRR7-AS1 effectively differentiated HCC specimens from normal tissues with an AUC of 0.875 (95% CI: 0.840 to 0.911). Moreover, the high PRR7-AS1 expression was associated with advanced clinical stage and poor prognosis of HCC patients. Importantly, the multivariate Cox proportional hazards model suggested that up-expression of PRR7-AS1 was an independent prognostic marker indicating shorter overall survival and disease-specific survival for HCC patients. Finally, we found that PRR7-AS1 expression was associated with the expression of NK CD56bright cells, Th2 cells, TFH, macrophages, Th1 cells, aDC, T helper cells, cytotoxic cells, DC, Tgd, neutrophils, and Th17 cells. Overall, the results of our study show that PRR7-AS1 was a biomarker that could be utilized to predict the prognosis of HCC patients and was linked to the infiltration of immune cells in HCC.
肝细胞癌（HCC）是一种侵袭性很强的恶性疾病，大量研究表明某些功能性长链非编码RNA（lncRNA）与多种癌症的进展有关。本研究的目的是通过数据库、生物信息学和统计分析来确定lncRNA PRR7-AS1（PRR7-AS1）是否与HCC相关。利用TCGA数据集对HCC中PRR7-AS1的表达模式进行研究。为了评估GIHCG作为一种预后工具的有效性，进行了生存分析和Cox回归分析。此外，还对HCC中PRR7-AS1的表达与免疫浸润之间的关系进行了研究。在本研究中，我们鉴定出125种在HCC中显著失调且与长期生存相关的lncRNA。在上述125种lncRNA中，我们将注意力集中在PRR7-AS1上。我们发现，与非肿瘤样本相比，PRR7-AS1在HCC样本中的表达明显上调。ROC分析显示，PRR7-AS1能够有效地区分HCC标本与正常组织，AUC为0.875（95%CI：0.840至0.911）。此外，PRR7-AS1的高表达与HCC患者的晚期临床分期和不良预后相关。重要的是，多变量Cox比例风险模型表明，PRR7-AS1的上调表达是一个独立的预后标志物，表明HCC患者的总生存期和疾病特异性生存期较短。最后，我们发现PRR7-AS1的表达与自然杀伤细胞CD56bright细胞、Th2细胞、滤泡辅助性T细胞、巨噬细胞、Th1细胞、浆细胞样树突状细胞、辅助性T细胞、细胞毒性细胞、树突状细胞、γδT细胞、中性粒细胞和Th17细胞的表达相关。总体而言，我们的研究结果表明，PRR7-AS1是一种可用于预测HCC患者预后的生物标志物，并且与HCC中免疫细胞的浸润有关。
